Biologics Commonly Used in Cutaneous Crohn's Disease - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Biologics Commonly Used in Cutaneous Crohn's Disease

Retrospective multicenter cohort highlights genital-predominant presentation patterns and frequent combination therapy use in cutaneous Crohn's disease.

  • By

  • Andrea Surnit

  • May 27, 2026

  • 3 min

Share

Objective:

To evaluate the outcomes of biologic or small-molecule inhibitor therapy in patients with cutaneous Crohn's disease (CCD).

Key Findings:
  • Include the terminal ileum as the most commonly involved gastrointestinal site.
  • Add the percentages of patients with no inflammatory bowel disease diagnosis, ulcerative colitis, and indeterminate colitis.
Interpretation:

Remove unsupported conclusions about treatment efficacy and timing.

Limitations:
  • Expand on the variability in treatment regimens across patients and centers.
Conclusion:

This study contributes to the limited literature on cutaneous Crohn's disease.

Original Source(s)

Biologics Commonly Used in Cutaneous Crohn's Disease

  • by Andrea Surnit

  • May 27, 2026

Related Content

High progesterone may be tied to syringoma

Elevated levels occurred in 29% of women with the condition compared with 6% of controls in a cross-sectional study.

Cupping vs UVB: Comparable Psoriasis Outcomes?

Randomized study found no statistically significant differences in disease improvement between treatments over 8 weeks.

AI Tool Finds More Long COVID Cases Than Codes

Nearly 90% of patients who met algorithmic criteria for postacute sequelae of SARS-CoV-2 infection had at least 1 chronic or potentially chronic condition requiring ongoing clinical management.